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In patients with chronic lymphocytic leukemia (CLL),
a single neoplastic antigen-specific B cell accumu-
lates and overgrows other B cells, leading to immune
deficiency. CLL is often treatedwith drugs that ablate
all B cells, leading to further weakening of humoral
immunity, and a more focused therapeutic strategy
capable of targeting only the pathogenic B cells
would represent a significant advance. One ap-
proach to this would be to develop synthetic surro-
gates of the CLL antigens allowing differentiation
of the CLL cells and healthy B cells in a patient.
Here, we describe nonpeptidic molecules capable
of targeting antigen-specific B cell receptors with
good affinity and selectivity using a combinatorial
library screen. We demonstrate that our hit com-
pounds act as synthetic antigen surrogates and
recognize CLL cells and not healthy B cells. Addi-
tionally, we argue that the technology we developed
can be used to identify other classes of antigen
surrogates.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a cancer of B lympho-
cytes that occurs via the relentless accumulation of a single an-
tigen-specific B cell clone (Chiorazzi et al., 2005). The nature of
the antigens that drive these events in CLL patients is generally
not known (Catera et al., 2008; Chu et al., 2010). Like many dis-
eases of the immune system, CLL is often treated with immuno-
suppressive compounds (Porter et al., 2011). For example,
monoclonal antibodies (mAbs) such as rituximab that eliminate
all CD20+ B cells are used commonly in combination with sys-
temic chemotherapy (Jaglowski et al., 2010). There is also great
interest in targeting molecules involved in, or associated with, B
cell activation, such as Bruton’s tyrosine kinase (Byrd et al.,
2013). However, although these B cell-targeted drugs are a1670 Chemistry & Biology 21, 1670–1679, December 18, 2014 ª2014great improvement over standard cytotoxic chemotherapy for
CLL and other B cell malignancies, they fail to discriminate be-
tween healthy and pathogenic B cells and thus leave the patient
without a functional humoral immune system. Therapeutics
selective for the pathogenic B cells would be of considerable
interest. An intriguing target for such a strategy would be the
antigen-specific surface membrane immunoglobulin (smIg)
component of the B cell receptor (BCR) of the pathogenic
lymphocytes.
Indeed, Levy and others have shown that vaccination of B cell
malignancy patients with their own immunoglobulins (Igs) can
induce useful anti-idiotype antibodies and T cells that selec-
tively target the pathogenic B cell clones and recruit effector
functions to them, resulting in their elimination (Houot and
Levy, 2009). Excellent clinical efficacy has been observed in
several cases, providing compelling evidence for the feasibility
of a strategy that selectively targets only the pathogenic cells.
However, there has been little progress on the development of
drug candidates that are selective for pathogenic B cells. In
this vein, one would require a highly selective ligand capable
of binding to the antigen-binding site of the leukemic Ig that
could be tailored to carry a toxic cargo. Whereas BCR-targeting
antibody-drug conjugates (ADCs) could be imagined as poten-
tial therapeutics, similar to the CD30-targeting ADC that is
approved for Hodgkin lymphoma (Bander et al., 2012), their pro-
duction is technically challenging (Adem et al., 2014) and anti-
bodies are able to carry only a small amount of drug payload,
necessitating the use of only a few extremely toxic compounds
(Anderl et al., 2013). Easily manipulable synthetic ligands for
leukemic Igs would have several advantages in this regard.
The synthetic ligands that recognize an antigen-specific CLL
Ig are 12-residue peptides isolated via phage display (Seiler
et al., 2009). Simple linear peptides are poor candidates for
this application because they have limited stability in serum.
More drug-like molecules with this type of binding selectivity
are unknown.
Here we report a potentially general approach to screen
synthetic one bead one compound (OBOC) libraries to identify
leukemic Ig-binding ‘‘antigen surrogates.’’ In this study, a li-
brary of molecules called COPAs (chiral oligomers of pentenoic
acids) (Aquino et al., 2012) (Figure 1) was mined for suchElsevier Ltd All rights reserved
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Figure 1. Design and Solid-Phase Synthesis
of a One Bead One Compound Library of
Chiral Oligomers of Pentenoic Acids
(A) General synthetic scheme for the solid-phase
synthesis of COPAs.
(B) General structure of the library used in this
study composed of a peptoid unit in the first po-
sition followed by three COPA units. The part of
the structure shown in gray is an invariant linker
present in all of the molecules. The library was
constructed by split and pool synthesis on 160 mm
TentaGel beads (0.29 mmol/g loading).
(C) Structures of the acid and amine submonomers
employed in the library synthesis. By using 20
amines at each of the four variable positions and
either (R)-2-methyl-5-chloro-3-pentenoic acid or
(S)-2-methyl-4-ethyl-5-chloro-3-pentenoic acid at
positions 2–4, the total theoretical diversity of the
COPA library was 1.28million compounds. 2.5 g of
resin (1.3 million beads) was used to create the
library.
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Ligands for Pathogenic CLL B Cell Receptorsligands. These polyketide-inspired molecules are calculated to
adopt discreet conformations determined by the absolute
chirality in each monomeric unit (Aquino et al., 2012). Thus,
oligomers of these units are predicted to be much ‘‘stiffer’’
than relatively ‘‘floppy’’ small peptides and peptoids and are
expected to be a superior source of protein ligands. In line
with this expectation, previous work (Aquino et al., 2012) has
shown that libraries of COPAs are capable of providing ligands
to protein targets for which no good binders could be mined
from a comparable library of peptoids. Indeed, COPA ligands
for antigen-specific CLL Igs are described in this study that
bind selectively with submicromolar affinities to a soluble, re-
combinant CLL patient-derived monoclonal Ig. When displayed
on a multimeric scaffold, these ligands distinguish between
cells that express different antigen-specific Igs. This work
represents a critical step in the development of nonpeptidic,
drug-like molecules capable of distinguishing pathogenic
from healthy lymphocytes.Chemistry & Biology 21, 1670–1679, December 18, 2014 ªRESULTS
A Screen for Synthetic ‘‘Antigen
Surrogates’’
We hypothesized that one could mine
COPA libraries for high affinity and selec-
tivity ligands that would recognize the an-
tigen-binding site of CLL patient-derived
smIgs by first denuding the library of li-
gands to conserved regions of IgGs and
then screening the remainder of the library
against one or a few antigen-specific tar-
gets. To test this idea, a library of COPAs
with the general structure shown in Fig-
ure 1 was constructed. The library, which
has a theoretical diversity of 1.28 million
compounds, was created using 2.5 g of
160 mm TentaGel beads (1.3 million
beads) using split and pool solid-phase
synthesis (Aquino et al., 2012). The beadswere suspended in buffer containing a high concentration of
BSA, and then exposed to amixture of human IgG antibodies ob-
tained from individuals that did not suffer fromCLL (Figure 2). After
washing, the beads were exposed to a red quantum dot-conju-
gated anti-human IgGsecondary antibody. The beads that bound
significant levels of the human IgGantibodies, or bounddirectly to
the secondary antibodypreparation, acquired an intense red fluo-
rescence. These beadswere removed from thepopulationmanu-
ally using a pipette under a low power fluorescence microscope.
We assumed that the remainder of the beads should be largely
devoid of ligands for conserved regions of human IgGs. Thus,
these beads were incubated with three soluble recombinant
CLLmonoclonal Igs, expressed and purified from human embry-
onic kidney 293T (HEK293T) cells (called CLL 068, 169 and 183,
respectively [100 nM each]). Again, subsequent incubation with
the fluorescently labeled secondary antibody was employed to
‘‘light up’’ the ‘‘hits.’’ A total of 110 beads fluoresced bright red
and were collected.2014 Elsevier Ltd All rights reserved 1671
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Figure 2. Schematic of the High-Throughput Bead-Based Screening Strategy
The combinatorial library shown in Figure 1 (1.2million beads) was first incubatedwith goat antihuman IgG secondary antibody conjugated to a red quantum dot
(QD) and beads that bound the secondary antibody, as judged by the presence of a red halo when observed under a low power fluorescence microscope, were
removed using a pipette. The rest of the beads were then incubated with a mixture of human IgGs obtained from individuals who did not have CLL, followed, after
washing, by the quantum dot-conjugated secondary antibody. Again, fluorescent beads were removed from the population. The denuded library was then
screened against a mixture of the CLL monoclonal Igs, CLL 068, 169, and 183 (100 nM each), followed by the QD-conjugated secondary antibody. The fluo-
rescent beads were pooled and stripped of protein. They were again exposed to control human IgGs and QD-conjugated secondary and beads with any
noticeable fluorescence were removed. Finally, the remainder of the beads was exposed to the three CLL antibodies, one at a time, followed by QD-conjugated
secondary antibody. The fluorescent beads were collected and placed in the wells of a microtiter plate (one bead per well). The compounds were released from
the bead using CNBr and the structures were determined using a combination of MALDI and LTQ-ETD mass spectrometry.
See also Figure S1.
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Ligands for Pathogenic CLL B Cell ReceptorsSince the re-synthesis and analysis of screening hits is themost
time-consuming portion of this type of discovery experiment, we
chose to repeat the experiment on these 110 putative hits. There-
fore, antibodies were stripped from the beads using a denaturing
buffer. After re-equilibration, the beads were again exposed to
control human IgG followed by the labeled secondary antibody.
Beads that emitted any observable fluorescence were eliminated
from the population. Those that did not were then exposed to
each of the three CLL Igs, one at a time, followed by labeled sec-
ondary antibody. At each step, the bright beads were harvested.
This resulted in 18 hits against CLL 169 and 13 hits against CLL
183 mAb. None of the beads bound significant levels of CLL
068, indicating that there were no high-affinity ligands for the an-
tigen-binding site of this Ig in the COPA library we used.
The beads displaying putative CLL 169 and 183 ligands were
placed in individual wells of a 96-well plate and treated with
CNBr to release the compounds into solution via cleavage of
the methionine residue in the conserved linker (Figure 1). The
molecules were analyzed by a combination of MALDI TOF-TOF
and electron spray ionization-electron transfer dissociation
(ESI-ETD) mass spectrometry (MS) (Sarkar et al., 2013). From
these data, the structures of 14 of the CLL 169 hits and nine of
the CLL 183 hits could be elucidated unambiguously (Figure S1
available online). All of these compounds were resynthesized1672 Chemistry & Biology 21, 1670–1679, December 18, 2014 ª2014and purified with high-performance liquid chromatography
(HPLC). In each case, a C-terminal cysteine was included to
facilitate site-specific labeling or surface immobilization of the
COPA molecule (Figure S2).
Biophysical Analysis of COPA-Antibody Binding
To evaluate the affinities of these small molecules for their target,
they were labeled with fluorescein and titrated with recombinant,
soluble Ig. Binding was monitored by fluorescence polarization
(FP) spectroscopy. Six of the 14 putative CLL 169 compounds
showed clear binding in this experiment, with the best ligand,
KMS5, exhibiting a KD of approximately 500 nM (Figure S3A).
Three of 9 putative CLL 183 ligands were validated in this assay
format exhibited KD values ranging from 0.6 mM to 3 mM (Fig-
ure S3B). Similar results were obtained when the compounds
were biotinylated, immobilized on streptavidin-coated ELISA
plates, and titrated with increasing amounts of soluble Ig (Fig-
ure 3A; Figure S3C). The derived KD values were lower, presum-
ably due to avidity effects.
The fact that the majority of the hits proved to be poor ligands
in solution or on ELISA plates was not surprising.Work in our lab-
oratory on small molecule-antibody interactions has shown that
TentaGel beads are heterogeneous and that a small fraction of
the bead population displays the compound at exceedinglyElsevier Ltd All rights reserved
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Figure 3. Binding Properties of the Library Screening Hits
(A) Biotinylated derivatives of six of the COPA screening hits found to bind to
CLL 169 in solution (Figure S3) were immobilized on streptavidin-coated ELISA
plates and titrated with the CLL 169 monoclonal Ig, followed, after washing, by
mouse-anti human IgG1-HRP. The KD of the highest affinity complex (KMS5)
was 90 ± 20 nM.
(B) Chemical structure of the biotinylated derivative of KMS5.
(C) Selectivity of KMS5 for CLL 169. Immobilized KMS5 was titrated with the
indicated antibodies, followed by the HRP-conjugated secondary antibody.
Error bars indicate SD of data obtained from three independent experiments.
See also Figure S3.
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Figure 4. Comparison of the COPA and Peptide Ligands for CLL 169
(A) Competition binding assays in which the CLL 169 Ig-containing solution
(120 nM) was blocked with the indicated concentration of soluble KMS5,
KMS5-dextran, 169-8 peptide, or a control peptide, then added to an ELISA
plate displaying immobilized KMS5. After washing, the level of bound antibody
was determined using mouse antihuman IgG1 antibody conjugated to HRP.
(B) Biotinylated derivatives of COPA KMS5 or peptide 169-8 (DNYAAA
LAQRAR) were immobilized on streptavidin-coated ELISA plates and titrated
with CLL 169 followed, after washing, by mouse-antihuman IgG1-HRP. Data
analysis and curve fitting were performed with GraphPad Prism 5.0 (GraphPad
Software) using a nonlinear regression method. Error bars indicate SD of data
obtained from three independent experiments.
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Ligands for Pathogenic CLL B Cell Receptorshigh density, which probably allows very weak ligands that
happen to be displayed at such densities on these rare beads
to stably capture an antibody on the surface due to ‘‘kinetic trap-
ping’’ effects (Doran et al., 2014).
Analysis of Binding Selectivity
To address the critical question of whether these compounds
target the antigen-binding site of the CLL-specific smIg, theChemistry & Biology 21, 1670–167three that exhibited the highest affinity for CLL 169 (KMS5,
KMS9 and KMS11) were immobilized on an ELISA plate and
titrated with various soluble Igs (CLL 014, CLL 068 and CLL
183) as well as human serum IgG. Two of the compounds,
KMS9 and KMS11, had modest selectivity for CLL 169 (Figures
S3D and S3E), whereas binding of KMS5 to CLL 169 was highly
selective (Figure 3C). Moreover, a scrambled version of KMS5
bound to CLL 169 with a much lower affinity (Figure 3). These
data argue that KMS5 recognized the antigen-binding site of
the CLL 169 Ig selectively.
To investigate this point further, a competition binding experi-
ment was carried out against a 12-residue peptide, called 169-8,
shown previously to bind the antigen-binding site of CLL 169
(Seiler et al., 2009). As shown in Figure 4A, soluble COPA
KMS5 competed binding of the CLL 169 IgG to immobilized9, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1673
AB
Figure 5. Flow Cytometry-Based Analysis of Ligand Binding to Cells Displaying Different CLL BCRs
(A) Schematic depiction of the assay. The pIg-gamma expression vectors were re-engineered by introducing a transmembrane (TM) domain at the C terminus of
the CH3 constant region to express CLL BCR as surface membrane immunoglobulin (smIg). HEK293T cells were transiently transfected with pIg gamma-TM and
Ig lambda/kappa plasmid pairs for CLL 014, CLL 068, CLL 169, andCLL 183monoclonal Igs and the expression levels of these smIgswere determined by staining
the cells with antihuman Ig Fc conjugated to allophycocyanin (anti-huIgFc-APC) flowed by analysis using flow cytometry. The plots indicate that all four of the
smIgGs were expressed (bottom row, panel b). The cells were then mixed with a biotinylated dextran polymer displaying 20-30 copies of the COPA KMS5 or
peptide 169-8. See also Figure S5.
(B) Flow cytometry plots obtained by treating the cells expressing the indicated smIg with the selecting antibody or dextran polymer, followed by PE-conjugated
streptavidin (SA-PE). See also Figure S7.
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Ligands for Pathogenic CLL B Cell ReceptorsKMS5, as expected. The same result was obtained when soluble
peptide 169-8was added to theCLL Ig, but a control soluble pep-
tide had no effect. These data argue that KMS5 and peptide 169-
8 compete for the same binding site on CLL 169 monoclonal Ig.
The competition data in Figure 4A also suggest that the affinity
of the COPA and the peptide are similar. To validate this, ELISA
experiments were conducted in which each compound, or a
control COPA compound or peptide, was immobilized on the
ELISA plate and titratedwithCLL 169 IgG. As shown in Figure 4B,
this experimental format confirmed that the affinities of the pep-
tide and COPA for CLL 169 are similar, with the peptide binding
approximately 2-fold more tightly (KD = 49 ± 11 nM for the pep-
tide-IgG complex, KD = 90 ± 20 nM for the COPA-IgG complex).
While the affinities are similar, the synthetic COPA compound is
resistant to degradation by human serum proteases (Figure S4)1674 Chemistry & Biology 21, 1670–1679, December 18, 2014 ª2014and thus would be preferable for selective drug delivery to
CLL cells.
Selective Recognition of Cells Expressing CLL-Specific
smIgs
With respect to theultimategoal of delivering toxic cargo toCLLB
cells, a critical issue is whether the COPA ligands can recognize
the smIgs for which they were selected. Ig heavy chain secreted-
expression plasmids (pIg-gamma) were re-engineered by intro-
ducing an IgG1 transmembrane (TM) domain at the C terminus
(Figures S5A and S5B). HEK293T cells were co-transfected
with these heavy chain and cognate light chain expression vec-
tors and the expression levels of surface membrane IgGs was
determined by staining the cells with antihuman Ig Fc specific
antibody conjugated to allophycocyanin (anti-huIgFc-APC) andElsevier Ltd All rights reserved
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Ligands for Pathogenic CLL B Cell Receptorsanalyzing by flow cytometry (Figure 5). As expected from a tran-
sient transfection, the population has a distribution of smIgG
expression levels, reflected in the width of the peak in the flow
cytometry plots.
Initial experiments, in which biotin-tagged KMS5 or biotin-
tagged 169-8 peptide were incubated with cells displaying CLL
169 or other BCRs were unsuccessful. Only a modest amount
of nonselective binding was observed (Figures S5C and S5D).
We hypothesized that this is due to the modest affinity of these
artificial CLL 169 ligands. Therefore, we turned to the multimeri-
zation of the peptide and COPA ligands in the hope that avidity
effects would provide a more favorable result. Dextran was cho-
sen as the backbone for these multimeric compounds given its
excellent solubility and biocompatibility. An estimated average
of 31 equivalents of KMS5 or peptide 169-8 was conjugated to
biotinylated dextran using the chemistry depicted in Figure S6.
To investigate if these multivalent conjugates indeed increase
the binding affinity for CLL 169 Ig, we carried out competition
ELISAs using KMS5 and dextran conjugated KMS5 (Figure 4A),
and 169-8 peptide and dextran conjugated 169-8 peptide (Fig-
ure S3F). Both of these experiments showed that multimerization
increased the affinity of the compound for CLL 169 Ig by more
than 10-fold (Table S1). These polymers were then incubated
with cells expressing the smIg form of CLL 169, one of three
alternative CLL smIgs, or cells lacking any smIg. Binding was fol-
lowed by staining with PE-conjugated streptavidin and flow
cytometry.
As shown in Figure 5, KMS5-Dextran showed significant bind-
ing to the cells expressing CLL 169, exhibiting a plot similar to
that observed when the CLL 169-displaying cells were incubated
with the antihuman Ig Fc-APC antibody. In contrast, only a small
amount of binding of KMS5 to cells expressing any of the other
CLL IgGs, or to the control cells, was observed. A similar result
was obtained with the 169-8 peptide-dextran conjugate, again
showing the similar behavior of the peptide and much smaller
COPA ligand.
Selective Binding of Multivalent Ligands with Primary
CLL Cells from Patients
Given these promising results using smIg-expressing cells, we
evaluated the extent that KMS5 selectively recognized the pa-
tient-derived primary CLL B cells. Frozen peripheral blood
mononuclear cells (PBMCs) containing the CLL 169 cells were
thawed and allowed to recover for 2 hr. To enrich for living B
cells, the PBMCs were subjected to a Ficoll gradient and then
a commercial kit (from Miltenyi Biotec) was employed to enrich
B cells in the population by selectively depleting non-B cells.
These cells were then incubated with biotin-tagged dextran-
KMS5, the equivalent construct displaying peptide 169-8, or
biotin-dextran conjugates displaying a control COPA or peptide.
After washing, the cells were then incubated with streptavidin-
conjugated PE (to monitor binding of the dextran conjugates to
the cells), anti-CD5-APC antibody and anti-CD19-FITC antibody
(to identify the CD5+/CD19+ CLL B cell population), and Po-Pro
dye (to stain dead cells). Four-color flow cytometry was carried
out to focus the analysis on binding of the dextran conjugates
to living CLL B cells (Figure 6A). As shown in Figure 6B, the bio-
tinylated dextran conjugates displaying the COPA KMS5 and the
peptide 169-8 associated with the CLL 169 B cells (Q2, CD5+/Chemistry & Biology 21, 1670–167CD19+), whereas biotinylated dextran conjugates displaying a
control COPA or peptide did not. On the other hand, the bio-
tinylated dextran conjugates did not exhibit any significant affin-
ity for the small population of normal (non-CLL) B cells (Q3,
CD5/CD19+) from the same patient (Figure 6C). Furthermore,
when the KMS5 and 169-8 conjugates were incubated with B
cells isolated from a different CLL patient, no significant binding
was observed (Figure 6D). In this case, the level of signal in the
PE channel observed when the KMS5 or 169-8 dextran-biotin
conjugates were incubated with the cells was essentially iden-
tical to that observed when the cells were mixed with the control
conjugates. Furthermore, these, in turn, were similar to that
observed when no dextran-biotin conjugate at all was used.
The KMS5 and 169-8 conjugates also did not bind to the T cell
population (Q1, CD5+/CD19) of CLL 169 PBMCs nor to the
CLL cell line MEC1 (Figure S7). The CLL 169 and control CLL
B cells had similar levels of smIg, as determined by staining
with antihuman IgM (Fc5m fragment specific) antibody as shown
in Figure S7D. Therefore, these data show that the KSM5-
dextran conjugate (as well as the peptide 169-8-dextran conju-
gate) is a highly selective ligand for native B cells displaying
the CLL 169 BCR. Notably, the binding is independent of the
isotype of the BCR (IgG on HEK293T cells and IgM on CLL B
cells), further corroborating selective targeting of the antigen-
binding site.
DISCUSSION
This study focused on determining the feasibility of screening
combinatorial libraries of unnatural, nonpeptidic compounds
for ligands to antigen-specific B cell receptors. Such molecules
could be used as ‘‘delivery agents’’ to bring toxic cargo or attract
effector functions selectively to specific Ig-bearing cells, pro-
viding an attractive strategy to attack pathogenic B cells while
sparing healthy B cells. High-affinity ligands for a CLL Ig could
also potentially be employed in a diagnostic mode, for example
in a flow cytometry-based assay to monitor the return of the
pathogenic B cell clone following initial chemotherapy. Although
BCR-binding (anti-idiotypic) antibodies and peptides have been
described previously, there are no reports of synthetic, unnatural
molecules capable of distinguishing B cells by their antigen
specificity.
A library of COPA molecules (Figure 1) was chosen as the
starting point. These compounds are insensitive to serum pepti-
dases that would rapidly degrade simple peptides (Figure S4).
The OBOC COPA library was first denuded of ligands for con-
served regions of human IgG molecules by screening it against
a mixture of antibodies from healthy controls and removing
binders with this step (Figure 2). The remainder of the library
was then screened against the recombinant, soluble version of
CLL Igs. These hits were then stripped and resubjected to the
screening conditions again to ensure that they were not artifacts.
The structures of the compounds that bound one of the CLL Igs
used in this study were then deduced by mass spectrometry
after release from the beads.
Several of the molecules identified in the screen proved to be
good ligands for a particular CLL smIg, as evidenced by binding
data from ELISA and fluorescence polarization experiments
(Figure 3 and Figure S3). KMS5, the best ligand for the CLL9, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1675
Figure 6. Flow Cytometry-Based Analysis of Ligand Binding to Primary B Cells from Patients
Purified CLL 169 B cells from PBMCs were incubated with multivalent compound (KMS5-dex-biot), peptide (169-8pept-dex-biot) or controls (COPA compound
and peptide that were not selected as CLL 169 ligands) followed by staining and flow cytometry analysis. The stains used were phycoerythrin (PE)-conjugated
streptavidin (SA-PE), antihuman CD5-APC antibody, antihuman CD19-FITC antibody, and Po-Pro dye, which dyes dead cells.
(A) Leukemic B cell populations (CD5+/CD19+/Po-Pro) and regular B cell populations (CD5/CD19+/Po-Pro) from CLL 169 patient are shown in Q2 and Q3
quadrants, respectively, on the dot plot.
(B) Observed level of SA-PE staining of CD5+/CD19+/Po-Pro CLL 169 B cells after incubation with the dextran conjugates indicated.
(C) Observed level of SA-PE staining of regular B cell populations (CD5/CD19+/Po-Pro) after incubation with the dextran conjugates indicated.
(D) Observed level of SA-PE staining of CD5+/CD19+/Po-Pro CLL B cells obtained from a different patient (not CLL 169) after incubation with the dextran
conjugates indicated.
See also Figure S7.
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binding site of the soluble version of this Ig with an affinity of
approximately 500 nM in solution (Figure S2A) and 90 nM
when immobilized on an ELISA plate, the difference presumably
reflecting avidity effects in the latter case. This affinity was similar
to that displayed by a 12-residue peptide ligand for CLL169 iso-
lated previously by phage display (Seiler et al., 2009) and the two
compounds competed for the antibody, indicating recognition of
the antigen-binding site.
Finally, while neither the biotin-labeled COPAKMS5 or peptide
169-8 could be seen to bind detectably to cells expressing the
CLL 169-specific Ig, probably due to the kinetic instability of
the complexes, selective binding was observed when either
molecule was displayed on a biotinylated dextran polymer (Fig-1676 Chemistry & Biology 21, 1670–1679, December 18, 2014 ª2014ure 5), again likely due to avidity effects. We have found that li-
gands displayed on dextran can engage both arms of antibodies
(Morimoto et al., 2014) and there is the further opportunity for
binding of a single dextran conjugate to multiple Igs on the cell
surface. In experiments using HEK293T cells expressing mem-
brane-anchored IgG, flow cytometry plots showed a clear shift
in the fluorescence of the CLL 169-expressing cells, but not cells
expressing CLL 014, CLL 068, CLL 183, or no BCR (Figure 5). For
the CLL 169-expressing cells, the gain in fluorescence was
similar when the cells were incubated with the peptide-dextran
complex, the COPA-dextran complex or an anti-Fc antibody,
indicating highly efficient binding. Similar results were observed
using native malignant B cells isolated form the CLL 169 patient
and not from CLL cells from a different patient whose smIg wasElsevier Ltd All rights reserved
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Ligands for Pathogenic CLL B Cell Receptorsstructurally distinct. Highly selective binding to the former was
observed (Figure 6).
In summary, we developed a potentially general protocol for
the isolation of nonpeptidic ligands for antigen-specific BCRs.
The molecules that result from this screen have modest affinity,
but high selectivity, for the antigen-binding site of the smIg of
the primary leukemic cells of the original CLL patient. By oligo-
merizing these molecules through conjugation to dextran, high
affinity is also achieved via avidity effects. We, and others,
have described the synthesis of a variety of different OBOC li-
braries containing unnatural molecules (Alluri et al., 2003; Gao
and Kodadek, 2013; Kritzer et al., 2005; Peng et al., 2006; Suwal
and Kodadek, 2013; Wu et al., 2014), all of which could be
applied to this screening protocol, thus allowing many different
chemotypes to be explored as antigen surrogates. Future work
will focus on the isolation of many such molecules, optimization
of the initial hits to higher affinity leads, and the creation of
chimeric molecules capable of delivering toxic cargo to B cells
expressing the target receptor.
SIGNIFICANCE
The ability to manipulate antigen-specific immune re-
sponses would have a significant impact in several areas
of biology and medicine. One such example is CLL, where
the antigen-specific B cell receptor is an attractive drug
target. Herewe describe examples of high affinity and selec-
tivity nonpeptide ligands capable of engaging antigen-spe-
cific CLL B cells. The development of this technology opens
the door to the development of chimeric ‘‘antigen-surro-
gate’’-toxin conjugates capable of killing only pathogenic
CLL cells without harming the normal function of the humor-
al immune system.
EXPERIMENTAL PROCEDURES
Design and Synthesis of COPA Library
The library was synthesized on 160 mm TentaGel MB NH2 resin (0.29 mmol/g
loading, 520,000 beads/g, from Rapp Polymere). Total theoretical diversity of
the library was 1.28 million and 2.5 g (2.5 3 520,000 beads) of resin was used
to cover at least one copy of each library member. The TentaGel beads were
derivatized with a peptoid linker as shown in Figure 1. A four-mer COPA li-
brary was synthesized following the linker using solid-phase sub-monomer
methods and split-and-pool techniques from (R) and (S) stereoisomers of
5-chloropentenoic acids and commercially available 20 different primary
amines. The pentenoic acid submonomers (as depicted in Figure 1) were syn-
thesized following the protocols described in our previous paper (Aquino
et al., 2012). To correlate differences in the mass of fragment ions with abso-
lute stereochemistry, the S-isomer was synthesized with an ethyl group at the
C4 position. The synthesis of COPA oligomers was described in detail by
Aquino et al. (Aquino et al., 2012). To determine the quality of the library, 24
random beads were isolated from the library and treated individually with
20 ml of CNBr solution to release the compounds. The parent ion mass of
the compounds was determined by MALDI-TOF and the sequence of the un-
known COPA tetramer was determined by multiple sequence specific prod-
uct ions obtained either from [M+2H]2+ or [M+3H]3+ or from both precursor
ions by ESI linear ion trap mass spectrometer (LTQ-ETD, ThermoFinnigan).
The method of structure elucidation of COPA oligomers by MALDI and
LTQ-ETD mass spectrometry was described in detail by Sarkar et al. (Sarkar
et al., 2013). From LTQ-ETD fragmentation patterns, the sequence of the
COPA oligomers was decoded unequivocally for 22 out of 24 (91%) random
beads. Representative spectra of MALDI-MS and ETD fragmentation patterns
from a random hit bead are shown in Figure S1.Chemistry & Biology 21, 1670–167Expression and Purification of CLL BCR IgGs
CLL monoclonal antibodies (CLL 014, CLL 068, CLL 169 and CLL 183) were
expressed as IgG1 isotype from IgG-lambda or IgG-kappa (light chain) and
IgG-gamma (heavy chain) expression plasmids. The cloning, expression,
and purification of mAbs were performed as reported by Seiler et al. (Seiler
et al., 2009)._Heavy and light chain variable gene segments from CLL clones
were amplified and subcloned into IgG1 heavy chain and IgG1 light chain
expression plasmids to express the CLL antibodies as IgG1 isotype. Human
embryonic kidney 293 T (HEK293T) cells were transiently co-transfected
with heavy and light chain plasmids and grown for 5 days in serum-free media
supplemented with nutridoma-SP (Roche Applied Science). CLL antibodies
were purified from media on a Protein G Plus agarose column (Thermo Scien-
tific), eluted in 1 3 PBS and stored in 1% BSA at 20C before use.
To display full-length IgG1 on cell surface, the heavy chain transmembrane
(TM) domain of human IgG1 was added to the C terminus of the human CH3
domain in expression vector pIg-gamma. Primers used for TM cloning are
shown in supporting information (Figure S4). The smIg were expressed on
transiently cotransfected HEK293 T cells and the expression level (CLL 014,
CLL 068, CLL 169, and CLL 183) was determined by staining cells with
Goat antihuman Fc-IgG conjugated to allophycocyanine (Fc-APC, from
Jackson ImmunoResearch Laboratory) and analyzed by flow cytometry (BD
FACSCanto II).
High-Throughput Bead-Based Screening of COPA Library
The TentaGel beads displaying the COPA library were pre-blocked with 1 3
TBST StartingBlock (Tris-buffered saline, pH 7.5, 0.05% Tween 20) containing
1%BSA before incubation with a 1:500 dilution of goat F(ab0)2-anti-human IgG
Qdot 655 (Life Technologies) for 45 min at room temperature (RT) in 13 TBST.
The beads were depicted under a fluorescence microscope (Olympus BX-51)
equipped with a 103 DAPI filter. Any beads emitting red light were collected
manually by amicropipette and discarded. The process was repeated by incu-
bating with 100 nM of pooled human IgG (from Sigma-Aldrich) following goat
F(ab0)2-antihuman IgG-Qdot. The denuded COPA library beads were incu-
bated with 300 nM of CLL BCR antibodies (100 nM each of CLL 068, CLL
169, and CLL 183) in binding buffer for 45 min at RT followed by incubation
with a 1:500 dilution of goat F(ab0)2-antihuman IgG Qdot for 45 min at RT. In-
dividual beads emitting red fluorescent light were collected manually using a
micropipette. A total of 110 beads (brightly fluorescent) were collected,
washed with 13 TBST, treated with 1% SDS at 90C for 10 min to remove
bound proteins, Qdot conjugated antibodies, and any nonspecific proteins
bound to the beads. In the final rounds of the selection process, initial hit beads
were incubated serially with CLL 068, CLL 169, and then CLL 183 to separate
the individual hits. A total of 18 hit beads against CLL 169 mAb and 14 hit
beads against CLL 183 were identified.
The hit beads were treated with 20 ml CNBr solution overnight to release
the compounds and the sequences of the compounds were elucidated by
MS and tandem MS/MS using a 4800Plus MALDI-TOF Analyzer (AB SCIEX)
LTQ-Orbitrap XL (Thermo Scientific) equipped with ETD at a resolving power
of 60,000 at m/z 400. The structures of the hit compounds were elucidated
by careful analysis of the product ions.
Biophysical Characterization of Initial Hit Compounds
Putative hit compounds (14 for CLL 169 and 9 for CLL 183) were resynthesized
with a fluorescein or biotin group at the linker position and purified on HPLC
using C18 reverse phase column. For the fluorescence polarization experi-
ment, fluorescein-COPA compounds (50 nM) were added to the serially diluted
CLL BCRmAbs in binding buffer (50 mM Tris, 100mMNaCl, 0.05% Tween 20,
pH 7.6) in a 384-well microtiter plate and incubated in the dark at RT until the
binding reached equilibrium. Fluorescence polarization (mP units) was
measured on an EnVision Multilabel Reader from Perkin Elmer. For ELISA,
biotin-tagged compounds and peptide were immobilized on a streptavidin
or neutravidin coated 96-well microtiter plate and titrated with serially diluted
CLL mAbs for 45 min at RT, followed by a 1:5,000 (1-Step Ultra TMB ELISA
substrate) or 1:20,000 (SuperSignal West Pico Chemiluminescent Substrate,
Thermo Scientific) dilution of IgG1 conjugated HRP (Southern Biotech) for
30 min at RT. The plates were treated with 1-Step Ultra TMB ELISA substrate
(3,30,5,50-tetramentyl benzidine) or West Pico chemiluminescent substrate
(Thermo Scientific) according to the supplier’s protocols and the data were9, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1677
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Redaer (Infinite 200Pro) using blue light. For competitive ELISA, KMS5 (or 169-
8) peptide was immobilized on to a neutravidin coated 96-well microtiter plate
and incubated with 120 nM of CLL 169 mAb for equilibrium binding. The multi-
well plate was then treated with serial dilution of KMS5 (self-competition) or
169-8 peptide or control (random side chains) for 45 min at RT followed by
anti-IgG1-HRP antibody (1:20,000) for 30 min at RT. SuperSignal West Pico
Chemiluminescent substrate was used for colorimetric development and the
luminescence was recorded on a Tecan Microplate Reader (Infinite 200Pro).
Serum Stability Test of COPA Compounds
Standard solutions of COPA compounds (1.0 mM) were prepared in DMSO.
KMS5 (4 ml) was added to a mixture of H2O (96 ml) and human serum
(100 ml; Sigma Aldrich), and incubated at 37C. Twenty microliter samples
were collected at 0, 24, 48, 72, 96, 120, and 144 hr time points. One microliter
of 0.2 mM internal standard COPA compound was added to the mixture and
immediately applied to a C18-spin column (Thermo Scientific). The COPA
compounds were purified following the supplier’s protocol and eluted with
40 ml of an elution solution (80% acetonitrile, 20% H2O). The resulting solution
was dilutedwith 0.1% formic acid and analyzed by LC-MS (LC/MS 1100 Series
equippedwith SBC18 column fromAgilent) with a linear gradient of (5% aceto-
nitrile, 0.05% formic acid/aqueous solution) to (80% acetonitrile, 0.05% formic
acid/aqueous solution).
Peptide Synthesis
The 169-8 peptide (CGSSG-DNYAAALAQRAR, gray-linker) was synthesized
following standard solid-phase peptide synthesis (SPPS) protocol using
HOBt (Hydroxybenzotriazole), HBTU (2-(1H-Benzotriazol-1-yl)-N,N,N0’,N0-tet-
ramethyluronium Hexafluorophosphate), DIPEA (diisopropylethyl amine) and
Fmoc-amino acid in DMF. Biotin-maleimide (Sigma) or Fluorescein-5-malei-
mide (Pierce) was conjugated to the peptide by Michael reaction through the
free thiol group on Cys. Peptides were purified on HPLC using C18 reverse
phase column, lyophilized, and stored at 20C before use. Control peptide
(CGSSG-FLAQKLWSALEY) was custom prepared from Sigma and the biotin
was conjugated to it by Michael reaction using biotin-maleimide (Sigma).
Multivalent COPA and Peptide Ligand Synthesis on Dextran Polymer
Amino-dextran was synthesized as previously reported (Nakamura et al.,
2010). The synthesis and chemical characterization of dextran conjugates
were described in detail in our previous paper (Morimoto et. al., 2014). In short,
dextran (500mg, averagemolecular weight 35,000–45,000, from Leuconostoc
mesenteroids, Sigma) was dissolved in 50 ml of anhydrous DMF and treated
with 126 mg of N,N0-carbonyldiimidazole and 250 ml of ethylenediamine. Ami-
nodextran was treated with biotin-NHS ester in DMSO at 4C for overnight to
conjugate biotin. COPA or peptide ligands were conjugated to the bio-
tinylated-dextran polymer through N-(a-Maleimidoacetoxy) succinimide ester
(AMAS, from Thermo Scientific) in DMSO for 2 hours in the dark. The unreacted
reactants were removed by filtering through Amicon Ultra 4 ml centrifugal filter
unit (10,000 NMWL, Millipore). The ligand-dextran conjugate in the filter unit
was recovered in 13 PBS according to the manufacturer’s protocol. The con-
centration of biotin in the solution was quantitatively determined using the
Fluorescence Biotin Quantitation Kit (Thermo Scientific). The procedure to es-
timate the number of ligands conjugated to dextran polymer is described in
detail in the Supplemental Experimental Procedures.
Cell Binding Assay by Flow Cytometry
HEK293T cells grown to 70% confluency 1 day after passage were transiently
cotransfected with IgG light chain (pIg-lambda or-kappa) and heavy chain
(pIg-gamma-TM) plasmids using 293-fectin transfection reagents (from Life
Technologies) following the manufacturer’s instructions. Cells were grown
for 48 to 72 hr at 37C in 5% CO2, collected from the flask, aliquoted
(0.5 3 106 cells) in each well of a microtiter 96-well plate and pre-blocked
with 2% BSA in 13 PBS containing 0.1% sodium azide. The cells were incu-
bated with biotin-tagged COPA compounds (50 nM) or 169-8 peptide
(20 nM) or dextran conjugated multivalent ligands for 30 min at 4C in binding
buffer (13 PBS, pH 7.4 containing 1% BSA and 0.1% sodium azide) followed
by 1:40 dilution of Streptavidin-Phycoerythrin (saPE, from BD Bioscience) and
Fc-APC for 30 min on ice. The cell surface expression of smIg (CLL 014, CLL1678 Chemistry & Biology 21, 1670–1679, December 18, 2014 ª2014068, CLL 169, and CLL 183) was detected as APC signal and the binding was
detected as PE signal by flow cytometry (BD FACSCanto II).
Binding Assay of Multivalent Ligand-Dextran Conjugates with
Primary CLL Cells from Patient
Cryopreserved PBMCs from CLL patient 169 (Jaglowski et al., 2010) were
thawed and recovered in AIM V media for 2 hr at 37C in 5% CO2. Resus-
pended PBMCs in 13 PBS were carefully passed through a density gradient
using Ficoll-Paque Plus (GE Healthcare) to remove the dead cells. B cells
were further purified using a B cell purification kit (Miltenyi Biotec) following
the supplier’s protocols. Four-color flow cytometry-based analysis was
carried out using streptavidin conjugated PE (to determine binding affinity),
antihuman CD5-APC antibody, and antihuman CD19-FITC antibody (to iden-
tify CD5+/CD19+ CLL B cell populations, BD Biosciences), and Po-Pro dye
(for the staining of dead cells, Life Technologies). Approximately 0.43 106 cells
were aliquoted into 96-well microtiter plate and incubated with 13 PBS con-
taining 2% BSA and 0.1% sodium azide for blocking followed by binding
with biotin-conjugated multivalent COPA, peptide ligand, control COPA
compound, and control peptide in binding buffer for 30 min on ice. The cells
were stained with streptavidin conjugated PE, anti-CD5-APC antibody, anti-
CD19-FITC antibody, and Po-Pro dye for 30 min on ice and analyzed on a
BD FACS Canto II for recognition to multivalent antigen surrogates.
SUPPLEMENTAL INFORMATION
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